Selective JAK1 Inhibitor Scaffold for Lower Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Jak1 inhibitors, such as tofacitinib and baricitinib, face limitations due to their non-optimal selectivity for Jak1 kinase, leading to tolerability issues and safety concerns, such as infections, anemia, and increased lipid levels, which hinder their full potential in treating autoimmune diseases like rheumatoid arthritis.
Innovation Solution
Development of novel 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives as selective Jak1 inhibitors, which are designed to target Jak1 kinase specifically, reducing off-target effects and improving safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective Jak inhibitors (tofacitinib, baricitinib) are used to treat autoimmune diseases, then Jak kinase activity is inhibited, but selectivity for Jak1 is insufficient leading to tolerability issues and safety concerns
Solution Approach 1:
The patent applies local quality by designing the inhibitor molecule with specific structural features (cyclic amine group in particular spatial and electronic configuration) that selectively interact with Jak1 kinase binding site, distinguishing it from Jak2, Jak3, and Tyk2. This localized molecular property enhancement achieves preferential binding to Jak1 while maintaining inhibition efficacy, thereby improving safety profile by reducing off-target effects on other Jak family members.
Solution Approach 2:
The patent employs parameter changes by modifying molecular parameters of the inhibitor compound, specifically the configuration and substitution patterns of the cyclic amine group. By adjusting these molecular parameters, the compound achieves optimal selectivity for Jak1 kinase, transforming a non-selective inhibitor into a selective one, thus resolving the contradiction between inhibition efficacy and safety profile.
2Productivity
If Jak1 inhibition is enhanced to improve treatment efficacy, then autoimmune disease symptoms are better controlled, but side effects such as infections and anemia increase
Solution Approach 1:
The patent applies local quality by enhancing the selective interaction between the inhibitor and Jak1 kinase through specific molecular structure design. The cyclic amine group's particular configuration creates a localized high-affinity binding site for Jak1, enabling potent inhibition of Jak1-mediated inflammatory pathways (improving treatment efficacy) while sparing other Jak family members that regulate hematopoiesis and immunity (reducing side effects like anemia and infections).
Solution Approach 2:
The patent converts the potential harm of Jak inhibition into benefit by achieving high selectivity for Jak1. The inhibitor selectively targets the harmful inflammatory signaling pathways mediated by Jak1 while preserving the beneficial functions of other Jak family members in immune regulation and blood cell formation. This transforms a potentially harmful non-selective inhibition into a beneficial selective therapy.
3Reliability
If selective Jak1 inhibitors are developed to reduce off-target effects, then safety profile improves, but development complexity and time increase
Solution Approach 1:
The patent applies segmentation by dividing the molecular design into distinct functional modules: a core scaffold structure and a cyclic amine group with specific substitution patterns. This modular approach allows systematic optimization of selectivity by independently designing and testing different cyclic amine variations, thereby managing development complexity through structured molecular engineering rather than random screening.
Solution Approach 2:
The patent uses the cyclic amine group as an intermediary element that mediates selective interaction with Jak1 kinase. This intermediary functional group acts as a molecular bridge that confers selectivity without requiring complete redesign of the entire molecule. The cyclic amine serves as a tunable mediator that can be optimized to achieve desired selectivity while building upon existing effective inhibitor scaffolds, thus managing development complexity.
Data Source
AI summary
The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic diseases or disorders.